Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

October 31, 2019

Conditions
Pancreatic Cancer
Interventions
DRUG

Chemotherapy

Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.

DRUG

Chemotherapy + ChemoRadiotherapy

Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.

Trial Locations (1)

32610

University of Florida Shands Cancer Center, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER

NCT01470417 - Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter